Intel stock spikes after report of possible US government stake
Investing.com - Barclays (LON:BARC) lowered its price target on FMC Corp . (NYSE:FMC) to $48.00 from $49.00 while maintaining an Overweight rating on the agricultural sciences company. The stock currently trades near its 52-week low of $32.83, with InvestingPro analysis suggesting the shares are undervalued.
The firm’s outlook for FMC’s fiscal year 2025 sales remains relatively unchanged, now modeling approximately flat sales year-over-year (down 1%) to around $4.2 billion. Barclays expects second-half expansion driven by Latin America and EMEA markets.
Barclays slightly raised its adjusted earnings per share estimate to $3.45, citing FMC’s second-quarter performance which exceeded expectations by approximately 20%.
The investment bank is monitoring how FMC’s new go-to-market model is performing, alongside credit and inventory levels as the company reports its second-half results.
Barclays maintains that FMC remains undervalued at its current trading multiple of 9x earnings.
In other recent news, FMC Corporation announced the registration of its Fundatis herbicide in Great Britain for use in winter wheat and barley. This development introduces a new tool for managing herbicide-resistant weeds, combining FMC’s Isoflex active ingredient with beflubutamid. Additionally, the company declared a regular quarterly dividend of 58 cents per share, payable in October 2025, maintaining its consistent dividend payment schedule. RBC Capital has raised its price target for FMC to $47 from $40, while Wells Fargo (NYSE:WFC) upgraded the company’s stock rating from Equal Weight to Overweight, citing positive market trends and strategic actions by management.
FMC’s Tremisia fungicide also received regulatory approval in Ukraine, marking the first introduction of its fluindapyr technology in the European, Middle East, and Africa region. This approval allows applications for oilseed rape, sunflower, and wheat across a significant expanse of Ukrainian farmland. RBC Capital adjusted its EBITDA estimates for FMC, maintaining its Q2 projection at $190 million and revising its fiscal year 2025 estimate to $895 million. Wells Fargo expressed confidence that 2024 will be a pivotal year for FMC’s earnings per share. These developments highlight significant strategic advancements and financial outlooks for FMC Corporation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.